Ameritas Investment Partners’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Ameritas Investment Partners’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.96K	Hold	50	–	–	﹤0.01%	3023
2025 Q4	$4.11K	Hold	50	–	–	﹤0.01%	3054
2025 Q3	$3.49K	Sell	50 -20	-29%	-$1.35K	﹤0.01%	3084
2025 Q2	$4.49K	Hold	70	–	–	﹤0.01%	3116
2025 Q1	$4.44K	Hold	70	–	–	﹤0.01%	2995
2024 Q4	$4.66K	Hold	70	–	–	﹤0.01%	3035
2024 Q3	$4.89K	Hold	70	–	–	﹤0.01%	3039
2024 Q2	$4.54K	Hold	70	–	–	﹤0.01%	3038
2024 Q1	$4.53K	Hold	70	–	–	﹤0.01%	2963
2023 Q4	$4.61K	Hold	70	–	–	﹤0.01%	2979
2023 Q3	$3.99K	Hold	70	–	–	﹤0.01%	3017
2023 Q2	$4.29K	Hold	70	–	–	﹤0.01%	3044
2023 Q1	$4.39K	Hold	70	–	–	﹤0.01%	2882
2022 Q4	$4.45K	Hold	70	–	–	﹤0.01%	2940
2022 Q3	$4K	Buy	70 +25	+56%	+$1.54K	﹤0.01%	2951
2022 Q2	$2K	Hold	45	–	–	﹤0.01%	3033
2022 Q1	$2K	Hold	45	–	–	﹤0.01%	3049
2021 Q4	$3K	Hold	45	–	–	﹤0.01%	3078
2021 Q3	$3K	Hold	45	–	–	﹤0.01%	3066
2021 Q2	$3K	Hold	45	–	–	﹤0.01%	3025
2021 Q1	$3K	Hold	45	–	–	﹤0.01%	3060
2020 Q4	$3K	Hold	45	–	–	﹤0.01%	3028
2020 Q3	$2K	Hold	45	–	–	﹤0.01%	3067
2020 Q2	$2K	Hold	45	–	–	﹤0.01%	3040
2020 Q1	$2K	Hold	45	–	–	﹤0.01%	2967
2019 Q4	$2K	Hold	45	–	–	﹤0.01%	2978
2019 Q3	$2K	Hold	45	–	–	﹤0.01%	3030
2019 Q2	$2K	Hold	45	–	–	﹤0.01%	3022
2019 Q1	$2K	Hold	45	–	–	﹤0.01%	2950
2018 Q4	$2K	Hold	45	–	–	﹤0.01%	2956
2018 Q3	$2K	Hold	45	–	–	﹤0.01%	3007
2018 Q2	$2K	Hold	45	–	–	﹤0.01%	2985
2018 Q1	$2K	Hold	45	–	–	﹤0.01%	2928
2017 Q4	$30K	Hold	45	–	–	﹤0.01%	2227
2017 Q3	$2K	Hold	45	–	–	﹤0.01%	2970
2017 Q2	$2K	Hold	45	–	–	﹤0.01%	2983
2017 Q1	$1K	Hold	45	–	–	﹤0.01%	2938
2016 Q4	$1K	Sell	45 -270	-86%	-$10.9K	﹤0.01%	1251
2016 Q3	$13K	Hold	315	–	–	﹤0.01%	1184
2016 Q2	$11K	Hold	315	–	–	﹤0.01%	1123
2016 Q1	$12K	Hold	315	–	–	﹤0.01%	1117
2015 Q4	$15K	Buy	315 +60	+24%	+$2.96K	﹤0.01%	1102
2015 Q3	$11K	Hold	255	–	–	﹤0.01%	1070
2015 Q2	$14K	Hold	255	–	–	﹤0.01%	1114
2015 Q1	$14K	Hold	255	–	–	﹤0.01%	1157
2014 Q4	$12K	Buy	+255	New	+$12.5K	﹤0.01%	1145

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Ameritas Investment Partners's PBE Position: Q1 2026 in Review

Ameritas Investment Partners held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 50 shares worth $3.96K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Ameritas Investment Partners first reported a position in PBE in Q4 2014 and has held it in 46 quarters since. The position peaked at $30K in Q4 2017. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.

Ameritas Investment Partners held 50 shares of Invesco Biotechnology & Genome ETF worth $3.96K as of Q1 2026.
Ameritas Investment Partners left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
Invesco Biotechnology & Genome ETF made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #3023 holding.
Ameritas Investment Partners first reported a position in Invesco Biotechnology & Genome ETF in Q4 2014 and has held it in 46 quarters since.
Ameritas Investment Partners's Invesco Biotechnology & Genome ETF position peaked at $30K in Q4 2017.
100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.